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16.1 Cell Therapy in Parkinson’s Disease
Parkinson’s disease (PD) is characterized by the progressive degeneration of
speciﬁc neuronal populations, particularly the dopaminergic neurons in the
substantia nigra (SN) projecting to the striatum. Loss of these neurons leads to a
lack of striatal dopamine, which is responsible for the principal motor
symptoms characteristic of the disease (tremor, rigidity, slowness of movement
and postural instability).1–3 Current PD pharmacological therapies are based
on the administration of pro-dopaminergic drugs, such as levodopa
(a dopamine precursor), agonists of dopamine receptors, or inhibitors of
dopamine degradation. However, none of these therapeutic strategies can stop
disease progression. Moreover, they become less eﬀective with time and can
eventually produce motor complications as dyskinesias.4
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During recent decades intrastriatal transplantation of dopamine-secreting
cells has been intensely investigated as a possible treatment to re-establish
striatal dopamine levels in PD patients.5,6 Among the diﬀerent cell types and
transplantation protocols assayed, the intrastriatal graft of fetal mesencephalic
neurons has provided the best clinical results.7–10 However, the clinical eﬃcacy
of this procedure has been questioned, since in two double-blind controlled
trials11,12 it showed little clinical beneﬁt and in some patients it induced the
appearance of disabling dyskinesias. In addition to these ‘neuroreparative’
dopamine cell transplants, neurotrophic factors have been shown to have
beneﬁcial eﬀects in several preclinical models of PD.13–17 Based on these
promising results cell therapy protocols that deliver trophic factors in the
striatum have also been applied to protect the nigrostriatal neurons aﬀected by
the ongoing neurodegenerative process. This ‘neuroprotective’ cell therapy aims
to diminish the progression of PD and even induce a partial reversal. Therefore,
the availability of dopaminergic and/or neurotrophic-factor-producing cells is a
major limitation in the search for eﬀective novel cell therapies for PD.
For over a decade, our group has studied the anti-Parkinsonian beneﬁts of
intrastriatal carotid body (CB) transplants. In this chapter we review the eﬀects
and mechanisms of the action of CB grafting on diﬀerent preclinical models of
PD as well as in two open, Phase I/II, clinical trials performed with Parkin-
sonian patients.
16.2 Anatomical and Physiological Features of the
Carotid Body
The CB is a small, paired, organ located at the carotid bifurcation
[Figure 16.1(a)]. It is a highly irrigated organ that receives blood through a
vessel branch originating from the external carotid artery. The CB is composed
of neural-crest-derived parenchyma, formed by the migration of sympatho-
adrenal progenitors from the superior cervical ganglion during fetal devel-
opment, and aﬀerent sensory nerve ﬁbers joining the glossofaringeal nerve.18
The adult CB parenchyma is organized in clusters of cells, called ‘‘glomeruli’’,
which are in close contact with capillaries and nerve ﬁbers [Figure 16.1(b)–(d)].
These glomeruli contain two main cell types: the neuron-like glomus, or Type I,
cells, surrounded by the glial-like sustentacular, or Type II, cells. Type I cells
are highly dopaminergic and can be easily identiﬁed by the expression of
tyrosine hydroxylase (TH; see Figure 16.1), the limiting enzyme in dopamine
biosynthesis. In contrast, Type II cells, which are TH-negative, express
classical glial markers such as the glial ﬁbrillary acidic protein [GFAP; see
Figure 16.1(d)].
The CB, the principal arterial chemoreceptor, mediates cardiorespiratory
homeostatic reﬂexes in response to changes in the chemical composition of the
blood. Hypoxemia, the main stimulus for CB,18,19 triggers hyperventilation and
sympathetic activation. Besides acute hypoxia, other parameters in arterial












cells.20 It is well established that Type I, or glomus, cells are electrically
excitable and function as the chemoreceptive elements of the CB. These cells
contain secretory vesicles with, among other neurotransmitters, high dopamine
content.21 They behave as presynaptic-like elements that upon stimulation
release neurotransmitters to activate aﬀerent sensory nerve ﬁbers of the IX
cranial nerve. Besides its role in sensing acute hypoxia, the CB is also special
among other adult neural or paraneural tissues because it can grow in
conditions of chronic hypoxemia. It is well known that sustained hypoxia
lasting several days stimulates CB cell proliferation and excitability,18,22 as well
as the synthesis of dopamine, due to TH induction.23 This special sensitivity to
hypoxia makes the CB particularly well-suited for intracerebral transplantation
due to its particular durability in low oxygen tensions, a normal environmental
condition in brain tissue,24 which is probably accentuated inside intracerebral
grafts. Recently, our laboratory has shown that, besides proliferation of TH-
positive cells, hypoxic CB growth is produced by the activation of a population
of resident stem cells in the adult organ. CB stems cells are the Type II,
sustentacular cells (or a subpopulation of them), that under physiological
hypoxia can proliferate and diﬀerentiate into new CB glomus cells.25 Type II
cells are non-excitable26,27 and comprise around 15–20% of the cells within the
CB. Classically, they had been considered to belong to peripheral glia with a
supportive function, but the recent identiﬁcation of Type II cells as peripheral
neural progenitors has generated interest in unraveling the interactions between
Type I and Type II cells in the CB.
Figure 16.1 Structural organization of the carotid body (CB). (a) Histological section
of the rat carotid bifurcation stained by in situ hybridization with a probe
against tyrosine hydroxylase mRNA (TH; blue). Note the localization of
the CB between the internal (ICA) and external (ECA) carotid arteries
and near to the superior cervical ganglion (SCG). (b) and (c) Clusters,
glomeruli, of TH1 glomus cells in the CB, revealed by immunohisto-
chemistry of TH [(b); brown] and TH in situ hybridization (c). (d)
Schematic representation of a CB glomerulus indicating Type I (red)
and Type II (purple) cells, blood vessels (V) and sensory nerve ﬁbers (nf).
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Another interesting physiological feature of the CB, of special value for its
use in neural protection and repair, is that it contains high levels of several
neurotrophic factors (brain-derived neurotrophic factor (BDNF), glial cell line
neurotrophic factor (GDNF) and artemin, among others).28–32 During recent
years we have shown that the CB is among the tissues with the highest levels of
GDNF in the adult rodent nervous system.30
16.3 Carotid Body Cell Therapy for Parkinson’s Disease
16.3.1 Initial Preclinical Studies: The Carotid Body as a Source
of Dopamine Cells
The use of CB grafts in PD animal models was initially proposed as a dopamine
cell replacement therapy, based on the high content in dopamine of CB glomus
cells.33,34 The ﬁrst study describing the use of CB glomus cells implants in PD
models was reported by Gash and colleges in the 1980s.35 The authors
performed grafts of enzymatically dispersed CB glomus cells in the hemi-
Parkinsonian 6-hydroxydopamine (6-OHDA) rat model, showing a slight
behavioral recovery after implantation. However, in this study only a small
number of CB glomus cells remained viable four weeks after grafting. In the
late 1990s our group performed CB grafts in the same hemi-Parkinsonian rat
model but using a diﬀerent experimental methodology, which consisted of the
use of CB cell aggregates instead of isolated glomus cells. CB cell aggregates
were used instead of dispersed cell since enzymatically treated glomus cells are
known to lose some of their physiological properties.36 Using this graft
procedure, the CB transplants produced a notable behavioral recovery three
months after implantation, and subsequent histological and functional analysis
revealed numerous clusters of TH-positive CB glomus cells and the
improvement of striatal dopamine release.37 During recent years several groups
have conﬁrmed that intrastriatal CB cell transplantation induces a marked
recovery of hemi-Parkinsonian rats, as determined by behavioral, histological
and neurochemical analyses.38–41
The favorable results obtained in the hemi-Parkinsonian rat model prompted
us to evaluate the beneﬁcial eﬀects of CB transplantation in a non-human
primate PD model. CB grafts were performed in Parkinsonian monkeys,
that were previously injected with the neurotoxin 1-methyl-4-phenyl-
1,2,3,6,-tetrahydropyridine (MPTP). CB transplantation induced, in this PD
model, a long-term (ﬁve month) amelioration of the Parkinsonian symptoms
that were accompanied by survival of CB glomus cells in the grafted striata.42
16.3.2 Recent Preclinical Studies: The Carotid Body as a
Biological Pump Releasing Dopaminotrophic Factors
As indicated above, the ﬁrst studies attempting transplantation of CB cells in












therapy. However, they unexpectedly revealed that the CB grafted striata
showed clear signs of re-innervation, in both rat and monkey PD models, with
a high density of striatal TH immunoreactive ﬁbers.35,37,42 These results posed
the question of whether the recovery induced by the CB grafts was due to
dopamine release by the transplanted glomus cells or because the transplants
secreted trophic substances that induced the re-generation of the host
dopaminergic striatal ﬁbers. Thus, we analyzed the long-term recovery after CB
grafting (between 5 and 15 months after transplantation) of hemi-Parkinsonian
rats with a degree of SN lesions higher than the animals analyzed in the
previous studies.35,37 Interestingly, CB-grafted animals could be clearly diﬀer-
entiated in two distinct groups on the basis of their behavioral and histological
characteristics. One group of rats showed a signiﬁcant and stable behavioral
recovery [Figure 16.2(a)] that correlated with an important re-innervation of
the grafted striatum [Figure 16.2(b)]. The origin of the ﬁbers re-innervating the
striatum was studied by retrograde labeling experiments, showing that these
ﬁbers originated from the remaining ipsilateral dopaminergic SN neurons
[Figure 16.2(c)]. In contrast, the other group of rats did not show behavioral
recovery despite the fact that they presented a large CB graft, well located in the
striatum and with numerous highly dopaminergic glomus cells [Figure 16.2(d)].
The histological examination of the nigrostriatal pathway of these animals
revealed a complete denervation of the transplanted striatum [Figure 16.2(e)]
and a total destruction of the ipsilateral SN [Figure 16.2(f)]. Altogether, the
behavioral and histological analyses of these animals suggested that the
beneﬁcial eﬀect of CB grafts on Parkinsonian animals was due to a trophic
eﬀect on dopaminergic nigrostriatal neurons, rather than to the local release of
dopamine by the transplant.39
The trophic action of CB grafts, suggested by these experiments, could be
explained by the fact that the adult CB produces high amounts of the
dopaminotrophic factor GDNF.29,30 GDNF has been shown to induce neuro-
protection and ﬁber outgrowth in several animal models of PD.13–16 Using
diﬀerent methodologies, includingAQ:3 RT-PCR, genetically modiﬁed animals
(GDNF/LacZ) and ELISA assay, we have shown that the CB is one of the few
areas in the nervous system expressing high levels of GDNF in adult life.30,39
Interestingly, CB GDNF is produced selectively in the dopaminergic glomus,
or Type I, cells and GDNF expression is maintained after intrastriatal trans-
plantation (Figure 16.3).30
The preliminary evidence supporting the trophic action of CB implants on
the nigrostriatal pathway was obtained using 6-OHDA hemi-Parkinsonian
rats.39 However, this model presents signiﬁcant limitations to identify and
study a trophic eﬀect. Firstly, it lacks an internal control to normalize the
variability of the lesion. Moreover, the acute lesion can mask the slow and
progressive protective eﬀects of the transplant on the nigrostriatal pathway.
Finally, the lesion of the nigrostriatal pathway can be non-uniform, thus it is
uncertain if the graft is placed in a region of the striatum that preserves the
dopaminergic axon terminals necessary for the uptake of the trophic factors
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can trophically protect the nigrostriatal pathway, and thus amielorate
Parkinsonism, we performed CB grafts in a novel systemic and chronic MPTP
mouse model. This chronic MPTP model recapitulates better the slow and
progressive death of dopaminergic neurons in PD and allowed us to test for the
trophic eﬀect of unilateral CB grafts on the nigrostriatal pathway, using for
comparison the contralateral sham-grafted striatum as a robust internal
control. With this experimental procedure we have recently shown that
intrastriatal CB grafts demonstrate a marked protective action on ipsilateral
SN neurons projecting to the area of the transplant [Figure 16.4(a) and (b)], and
produce ﬁber outgrowth in the striatum. In fair consistency with a classical
trophic eﬀect, the trophic protection exerted by the CB graft on the nigro-
striatal dopaminergic neurons showed dose–response dependence in relation to
the size of the CB transplant [Figure 16.4(c)]. Moreover, the dose-dependent
Figure 16.2 Functional and histological analysis of long-term CB-grafted hemi-
Parkinsonian rats. (a) Rotational behavior of hemi-Parkinsonian rats
with optimal functional recovery, before (BT) and after (AT) CB trans-
plantation. (b) and (c) Histological sections of the striatum [(b), after TH
immunohistochemistry] and SN [(c) labeled with the ﬂuorescent
retrograde tracer ﬂuorogold] of a rat with optimal functional recovery,
showing a signiﬁcant re-innervation of the grafted striatum (b) arising
from the remaining ipsilateral SN neurons (c). (d) Rotational behavior of
hemi-Parkinsonian rats with bad functional recovery, before (BT) and
after (AT) CB transplantation. (e) and (f) The histological examination,
after TH immunohistochemistry, of the nigrostriatal pathway of these
rats showed a complete denervation of the transplanted striatum (e) and
a total destruction of the ipsilateral SN (f). t-Test *po0.05.












trophic action of CB transplants was also analyzed by performing CB grafts
from heterozygous GDNF/lacZ (GDNF1/) mice, which contained less
GDNF than wild-type controls.43,44 Interestingly, intrastriatal grafting of
GDNF1/ CB showed a reduced, non-signiﬁcant, protection of nigral neurons,
compared with wild-type (GDNF1/1) CB grafts that, as indicated before,
produced a strong preservation of SNAQ:5 [Figure 16.4(d)].44 Altogether, these
results strongly support the view that the beneﬁcial action produced by CB
Figure 16.3 GDNF production in CB glomus cells in situ and after intrastriatal
transplantation. (a)–(c) GDNF expression [blue precipitate, (a)] in a
dispersed TH-positive [(b), red ﬂuorescence] and GFAP-negative (c) CB
Type I or glomus cell. (d)–(f) Lack of GDNF expression in a Type II or
sustentacular CB cell, showing the characteristic GFAP expression [(f),
green ﬂuorescence] and absence of TH (e). The cells are representative
examples obtained from primary cultures of heterozygous GDNF/LacZ
CB, which were stained for Xgal and immunoﬂuorescence (TH and
GFAP). (g) GDNF protein content measured by ELISA in CB and other
neural or paraneural tissues (SCG¼ superior cervical ganglion,
AM¼ adrenal medulla, Zuck¼Zuckerland’s organ). (h) and (i) GDNF
expression in intrastriatally grafted CB glomus cells. Note the GDNF
expression (blue stain) in an intrastriatal implant of a heterozygous
GDNF/lacZ CB (h), counterstaining with TH antibodies the blue
GDNF-lacZ dots clearly appeared in the transplanted glomus CB cells
(i). t-Test *po0.05.











Carotid Body Transplants as a Therapy for Parkinson’s Disease 367
grafting is compatible with a retrograde trophic action of the grafted tissue on
the nigrostriatal pathway, and positively correlates with the size and the GDNF
expression level of the CB implant.
Based on the high content of trophic factors, especially GDNF, encountered
in the adult CB, diﬀerent authors have proposed the cografting of CB and
ventral mesencephalic neurons to improve the survival and the anti-
Parkinsonian eﬀects of the grafted fetal dopaminergic neurons.40,45 Moreover,
it have been shown that CB grafts can promote an increase in the number of
striatal dopaminergic cells in Parkinsonian monkeys.46 This eﬀect of CB
Figure 16.4 Trophic protection of SN neurons by CB grafts and dose-dependence
regarding transplant size and GDNF expression. (a) Scheme of the
experimental protocol. Brieﬂy, unilateral striatal CB grafts were
performed with a sham graft in the contralateral hemisphere, afterwards
mice were chronically (20mgkg1, three times per week over three
months) treated with MPTP. (b) Brain coronal sections after immuno-
chemistry of TH showing the trophic protection exerted by CB graft
(inset on right panel) on the nigrostriatal pathway. Note the stereological
quantiﬁcation, expressed as the percentage of sham-grafted side, of TH1
nigral neurons on the right-bottom plot. (c) Graph illustrating the linear
regression (r¼ 0.534, po0.05) established between the nigral protection
exerted by the CB transplant (ordinate) and the graft volume (abscissa).
(d) Stereological quantiﬁcation of dopaminergic SN neurons of MPTP-
treated mice grafted with GDNF1/ or GDNF1/1 CBs. GDNF1/ CB-
grafted mice showed a reduced and not signiﬁcant (n.s.) protection of SN
neurons compared with wild type (GDNF1/1), which induces a notable
protection of these dopaminergic neurons. t-Test *po0.05, **po0.001.












grafting has been attributed to the release of GDNF by the transplant, because
the administration of neurotrophic factors can produce similar eﬀects.47 In
addition, a neuroprotective eﬀect of CB grafts has been also suggested in
experimental stroke.48,49
16.4 Clinical Studies of Carotid Body
Autotransplantation on Parkinson’s Disease
Patients
The signiﬁcant improvement induced by the CB graft in the diﬀerent PD animal
models encouraged the evaluation of the eﬃcacy of CB transplantation in PD
patients. In addition to their dopaminergic nature and their high content of
neurotrophic factors, especially GDNF, the CB presents an important clinical
advantage because its unilateral surgical re-section has no signiﬁcant side-
eﬀects.50 Two pilot Phase I/II open trials were performed to test the feasibility,
safety and clinical eﬃcacy of CB autotransplantation in Parkinsonian
patients.51,52 The experimental procedure in these trials consisted of unilateral
removal of the CB and subsequent preparation of CB cell aggregates with ﬁne
scissors that were bilaterally placed in each putamen. Thirteen patients with
advanced PD assessed before and up to 1–3 years after surgery were included in
the two clinical trials. The primary outcome measure was change in motor ability
[motor subscale (Part III) of the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS)] in the ‘‘oﬀ’’ medication state evaluated by an independent neurologist
in a blinded fashion from masked and randomly presented video sequences.
Clinical improvement in the primary outcome measure was observed in 10 of
12 patients, being maximal at 6–12 months after transplantation (5–74%; 23%
of mean improvement). Although a long-term trend towards presurgical
clinical status was generally observed, a sustained improvement was detected in
three of the six patients evaluated three years after grafting. In seven patients
18F-DOPA positron emission tomography (PET) scans were performed before
and one year after transplantation.52 In these patients we observed a trend
towards a 5% increment in intraputaminal 18F-DOPA uptake instead of the
expected yearly decrement, characteristic of advanced PD patients, estimated in
approximately 10% of patients.53 Because of technical problems one patient
was successfully transplanted in only one hemisphere and received a needle
track in the contralateral hemisphere. Interestingly, this patient only showed
motor improvement in the contralateral hemi-body.51 The results obtained
in this patient indicated that the clinical eﬀect of CB transplant is mediated by a
speciﬁc action of the grafted cells, as it occurs in the diﬀerent animal models of
PD, rather than by placebo or some unspeciﬁc eﬀect of the surgical procedure.
The clinical outcome obtained by autotransplantation of CB is similar to the
eﬀects reported by grafting fetal dopaminergic neurons.11,12 However, CB-
grafted patients did not develop dyskinesias unlike those patients subjected to
fetal neuron transplantation. This could be related to the fact that the number











Carotid Body Transplants as a Therapy for Parkinson’s Disease 369
fetal grafts. Hence, it seems that the main action of CB-grafted cells is a
neuroprotective eﬀect on nigrostriatal neurons rather than solely dopamine cell
replacement. Additionally, the most signiﬁcant predictive factors for motor
improvement in the patients analyzed were the histological integrity of the CB
(an estimation of the number of dopaminergic-GDNF-secreting cells) and a
milder disease severity, which further indicated that the main action of the CB
transplant is a trophic neuroprotective eﬀect.
16.5 Conclusions and Perspectives
During recent years several studies have demonstrated that intrastriatal
transplantation of CB cells produces a signiﬁcant histological and functional
recovery in various preclinical models of PD.37,39,42,44 These beneﬁcial actions
of CB grafting have been independently conﬁrmed by several authors.38,40,46
Detailed analyses of the mechanism underlying the anti-Parkinsonian action of
CB transplants have revealed that their eﬀect is mainly due to a trophic
stimulation of the nigrostriatal pathway, producing both striatal ﬁber
outgrowth and protection of the SN neurons.39,44 This trophic action is
mediated, at least in part, by the release of GDNF by the CB graft.30,44 Thus,
dopaminergic glomus CB cells appear to be ideally suited for the endogenous
delivery of neurotrophic factors, especially GDNF, in PD and probably in
others neurological disorders.
Two pilot Phase I/II open trials have shown that CB autotransplantation is a
safe and feasible procedure with potential clinical applicability to treat PD,
producing a clinical improvement51,52 similar to that obtained after fetal
mesencephalic transplantation.11,12 However, the eﬀectiveness of CB cell
therapy observed in clinical trials is considerably lower than in experimental
models. This diﬀerential eﬃcacy had led us to revaluate experimentally putative
limitations that can aﬀect the clinical outcome of CB transplantation, such as
the severity of the disease, patient age and the amount (and integrity) of CB
tissue grafted. The inﬂuence of these variables on anti-Parkinsonian CB cell
therapy is currently under investigation. We are analyzing the eﬀect of the
donor and receptor age on the trophic protection exerted by the CB graft on the
nigrostriatal pathway. Moreover, we are testing the putative eﬃcacy of in vitro
expanded CB cells, based on the recent identiﬁcation of adult CB stem cells that
can proliferate and diﬀerentiate into new dopaminergic and GDNF-producing
CB glomus cells.25 The results obtained in these on-going scientiﬁc projects
would help to design new clinical approaches that could eventually improve the
outcome of CB transplantation.
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